Skip to main content
. 2018 Aug 13;10(8):1082. doi: 10.3390/nu10081082

Figure 4.

Figure 4

Ex vivo assay of circulating DPP-IV in human serum: (a) sitagliptin showed a dose-dependent inhibition of circulating DPP-IV with an IC50 of 0.2 µM; (b) Lup1 inhibited circulating DPP-IV activity by 18.1% and 24.7% at 100 µM and 300 µM, respectively. Soy1, at the same concentrations, showed a slightly higher inhibitory activity of 27.7% and 35.0%, respectively. Data are the means ± SD of three experiments performed in triplicate. *: p > 0.05.